AR and Familial prostate cancer: These findings underscore luteolin’s potential to enhance the effectiveness of existing CRPC therapies and its promise as a novel therapeutic strategy targeting AR-V7 and associated pathways, thereby improving treatment outcomes for patients with advanced prostate cancer.